The mixed tocopherols are known for its properties such as antioxidant, immune enhancing, and anti-inflammatory and anti-platelets aggregation effects and plays most effective role in the daily diet. The mixed tocopherols have various benefits such as prevention and cure of cardiac diseases, joint pain, and high blood pressure, which resulted in the demand of the mixed tocopherols from the pharmaceutical industry.
Category: Pharmaceuticals
Press release distribution, EDGAR filing, XBRL, regulatory filings
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alexion Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 )–Levi & Korsinsky reminds shareholders of a class action lawsuit on behalf of shareholders of Alexion Pharmaceuticals, Inc. who purchased shares between February 10, 2014 … SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of TerraVia Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 )–Levi & Korsinsky reminds shareholders of a class action lawsuit on behalf of shareholders of TerraVia Holdings, Inc. who purchased shares between August 8,… DPLO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Diplomat Pharmacy, Inc. and a Lead Plaintiff Deadline of January 9, 2017 )–The Law Offices of Vincent Wong … (more)
Press release distribution, EDGAR filing, XBRL, regulatory filings
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alexion Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 )–Levi & Korsinsky reminds shareholders of a class action lawsuit on behalf of shareholders of Alexion Pharmaceuticals, Inc. who purchased shares between February 10, 2014 … SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of TerraVia Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 )–Levi & Korsinsky reminds shareholders of a class action lawsuit on behalf of shareholders of TerraVia Holdings, Inc. who purchased shares between August 8,… DPLO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Diplomat Pharmacy, Inc. and a Lead Plaintiff Deadline of January 9, 2017 )–The Law Offices of Vincent Wong … (more)
Bristol-Myers Squibb and Calithera Biosciences Announce Clinical…
Bristol-Myers Squibb Company and Calithera Biosciences , Inc. , a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo in combination with Calithera’s CB-839 in patients with clear cell renal cell carcinoma . CB-839 is an orally administered glutaminase inhibitor currently in Phase 1/2 clinical studies.